Predictive Biomarkers Market Trends

  • Report ID: 3175
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Predictive Biomarkers Sector: Growth Drivers and Challenges

Growth Drivers

  • Expanding Use of Biomarkers for Diagnostic Purposes– The use of biomarkers in numerous sectors, such as personalized medicine, companion diagnostics, disease risk assessment, and drug development, is expected to drive market growth. Predictive biomarkers assist in determining the likelihood of an adverse reaction to a specific treatment modality, its early diagnosis, and its severity. The use of predictive biomarkers might drastically lower healthcare costs since they anticipate whether a given medication will be effective or not, which gives them an edge over predisposition biomarkers.

  • Growing Demand for Personalized Medicine- Numerous scientific breakthroughs, and increased demand for the discovery of novel drugs, have led to the rise of personalized medicine. This has significantly driven market growth. Biomarkers are crucial instruments that help in personalizing medical treatments to individual patients which means providing the right treatment to the right patient, at the right dose, at the right time.

Challenges

  • Lack of Efficient Regulatory and Reimbursement Systems- The regulatory and reimbursement processes in the majority of OECD nations are not well suited to handle this new influx of biomarker-based diagnostic tests. Modern biomarker-based diagnostics that produce complex data needing in-depth analysis and interpretation are not well adapted to the regulatory systems now in place as they were designed around simple diagnostic tests. The adoption of these technologies in the clinical arena may be hampered by inadequately designed regulatory and reimbursement systems, which may also serve as a deterrent to further biomarker research. The processes for requesting approval and/or compensation are still being developed at this time.

  • High Capital Investment

  • Technical Difficulties with Collecting and Storing Samples


Base Year

2024

Forecast Year

2025-2037

CAGR

18.8%

Base Year Market Size (2024)

USD 24.12 billion

Forecast Year Market Size (2037)

USD 226.46 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of predictive biomarkers is evaluated at USD 31.92 billion.

The predictive biomarkers market size was over USD 24.12 billion in 2024 and is poised to exceed USD 226.46 billion by 2037, growing at over 18.8% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of chronic diseases, such as cancer, and diabetes across the globe and the growing geriatric population will boost the market growth.

North America industry is anticipated to account for largest revenue share of 35% by 2037, backed by advanced research and development activities in the healthcare sector.

The major players in the market are Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH, Danaher Corporation, Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., Meso Scale Diagnostics, LLC
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos